scPharmaceuticals从Perceptive Advisors获得1.25亿美元的非稀释性融资，用于偿还债务和FUROSCIX商业化。 scPharmaceuticals secures $125M non-dilutive financing from Perceptive Advisors for debt repayment and FUROSCIX commercialization.

scPharmaceuticals Inc.宣布对普通股或预融资期权进行保证性公开发行,保证人有权在30天内购买15%的股票. scPharmaceuticals Inc. announces an underwritten public offering of common stock or pre-funded warrants, with option for underwriters to buy 15% more within 30 days. 公司还获得了来自生命科学投资者Perceptive Advisors的高达1.25亿美元的非稀释性融资. The company also secures up to $125M non-dilutive financing from Perceptive Advisors, a life-sciences investor. 这两种交易的收益将用于偿还债务和进行FUROSCIX的商业化。 Proceeds from both transactions will be used for debt repayment and ongoing commercialization of FUROSCIX.